The short version of N-terminal modification fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-16. Anything still debated is marked as such rather than presented as settled.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
=== Gastric bypass surgery === Various methods of gastric bypass or gastric restriction surgery are used to treat morbid obesity. Roux-en-Y gastric bypass surgery (RYGB) but not sleeve gastric bypass surgery or gastric banding, increases the risk of vitamin B12 deficiency and requires preventive post-operative treatment with either injected or high-dose oral supplementation. For post-operative oral supplementation, 1000 μg/d may be needed to prevent vitamin deficiency.
Acoustic and seismic metamaterials are also research areas. Metamaterial research is interdisciplinary and involves such fields as electrical engineering, electromagnetics, classical optics, solid state physics, microwave and antenna engineering, optoelectronics, material sciences, nanoscience and semiconductor engineering. Recent developments also suggest potential applications of metamaterials in optical computing, with metamaterial-based systems theoretically being able to perform certain tasks more efficiently than conventional computing.
== Biochemistry == Unlike most amino acid transporters in the exchange of Na+ with amino acid symporters, proton-coupled amino acid transporters function as H+ with amino acid symporters. They are located within the luminal surface of the small intestine and within lysosomes, so their action functions in absorption in the intestine and in the efflux pathway after intralysosomal digestion. Unlike typical mammalian amino acid transporters which function in exchanging Na+/amino acid symporters, these- transporters function in exchanging H+/amino acid symporters. The activity of transporters, such as Proton-coupled amino acid transporter 1 and Proton-coupled amino acid transporter 2 can be measured at the apical membrane of the human epithelial layer of cells which are loaded with pH sensitive dyes. The change in membrane potential can be measured by the absorption of pH sensitive dyes and the associated influx of H+ ions. The proteins involved in these transporters are consider anion exchangers
== Background == In general, it is difficult to decompose a combined wave–mean motion into a mean and a wave part, especially for flows bounded by a wavy surface: e.g. in the presence of surface gravity waves or near another undulating bounding surface (like atmospheric flow over mountainous or hilly terrain). However, this splitting of the motion in a wave and mean part is often demanded in mathematical models, when the main interest is in the mean motion – slowly varying at scales much larger than those of the individual undulations. From a series of postulates, Andrews & McIntyre (1978a) arrive at the (GLM) formalism to split the flow: into a generalised Lagrangian mean flow and an oscillatory-flow part. The GLM method does not suffer from the strong drawback of the Lagrangian specification of the flow field – following individual fluid parcels – that Lagrangian positions which are initially close gradually drift far apart. In the Lagrangian frame of reference, it therefore becomes often difficult to attribute Lagrangian-mean values to some location in space. The specification of mean properties for the oscillatory part of the flow, like: Stokes drift, wave action, pseudomomentum and pseudoenergy – and the associated conservation laws – arise naturally when using the GLM method. The GLM concept can also be incorporated into variational principles of fluid flow.
Carlton – The rivalry between Essendon and Carlton is considered one of the strongest in the league. With the teams sharing the record of 16 premierships, both sides are keen to become outright leader, or if out of the finals race, at least ensure the other doesn't. In recent years, the rivalry has thickened, with Carlton beating the 1999 Minor Premiers and premiership favourites by 1 point in the Preliminary Final. Other notable meetings between the two clubs include the 1908, 1947, 1949, 1962 and 1968 VFL Grand Finals and 1993 AFL Grand Final, with some decided by small margins. Of the 6 Grand Finals played out of the two clubs, Essendon has won 3 and Carlton has won 3. Collingwood – In the early days of the VFL, this rivalry grew out of several Grand Final meetings: 1901, 1902 and 1911. The teams didn't meet again in a Grand Final until 1990 when Collingwood won to draw level with the Bombers on 14 premierships and deny the Bombers a chance to join Carlton with 15 flags. Since 1995, the clubs face off against each other annually in the Anzac Day clash, a match which is described as the second biggest of the season (behind only the Grand Final). Being possibly the two biggest football clubs in Victoria, regardless of their position on the ladder, this game always attracts a huge crowd, and it is a match both teams have a great desire to win regardless of either team's season prospects. The rivalry thickened further in 2023 when Collingwood joined Essendon and Carlton with a record 16 premierships.
Sources: en.wikipedia.org
Amazon, America's second largest employer, eliminated cannabis testing in job pre-screening, where not required by government regulations, stating, "Pre-employment marijuana testing has disproportionately affected communities of color by stalling job placement." In a survey of 45,000 companies worldwide, 9% reported the elimination of testing to improve hiring. In 2022, thousands of US truck drivers were taken off the road after testing positive for cannabis, contributing to a severe driver shortage; a conflict between the majority of states with some form of cannabis legalization, and the federal Department of Transportation's zero-tolerance cannabis policy, even for medical use, is cited as a problem.
== History == During the 1980s, Jean-Pierre Raufman worked as a postdoctoral researcher at the National Institutes of Health for John Pisano, a biochemist who specialized in collecting venom from various animals and looking for novel substances that could affect human physiology. In the course of this work, Raufman focused on the Gila monster, because he was curious about its practice of eating once or twice per year. He reported that Gila monster venom had biologically active molecules that provoked inflammation of the pancreas in test animals. In 1992, after learning of Raufman's findings, John Eng of the Veterans Administration Medical Center in New York City used radioimmunoassay to isolate a novel substance from Gila monster venom. The new substance, which Eng called exendin-4, was similar to GLP-1 in that it reduced blood glucose in diabetic mice, but exendin-4 had a much longer half-life than GLP-1, whose extremely short half-life had defeated earlier attempts to turn it into a drug. Eng filed a patent application for exendin-4 in 1993. He then spent three years searching for a pharmaceutical industry partner interested in commercializing exendin-4. In 1996, Amylin Pharmaceuticals licensed Eng's patent and created a synthetic version of exendin-4 called exenatide. In 2002, Eli Lilly and Company partnered with Amylin to develop exenatide and secure approval to market the drug. Exenatide's 2005 approval by the U.S.
2-, alpha-, or α-amino acids have the generic formula H2NCHRCOOH in most cases, where R is an organic substituent known as a "side chain". Of the many hundreds of described amino acids, 22 are proteinogenic ("protein-building"). It is these 22 compounds that combine to give a vast array of peptides and proteins assembled by ribosomes. Non-proteinogenic amino acids may arise through nonribosomal peptide synthesis. Modified amino acids, by contrast, typically result from post-translational modification.
== Research == The use of a nitric oxide delivery system (glyceryl trinitrate patches) applied over the area of maximal tenderness was found to reduce pain and increase range of motion and strength. A promising therapy involves eccentric loading exercises involving lengthening muscular contractions.
Lysyl hydroxylases (or procollagen-lysine 5-dioxygenases) are alpha-ketoglutarate-dependent hydroxylases enzymes that catalyze the hydroxylation of lysine to hydroxylysine. Lysyl hydroxylases require iron and vitamin C as cofactors for their oxidation activity. It takes place (as a post-translational modification) following collagen synthesis in the cisternae (lumen) of the rough endoplasmic reticulum (ER). There are three lysyl hydroxylases (LH1-3) encoded in the human genome, namely: PLOD1, PLOD2 and PLOD3. From PLOD2 two splice variant can be expressed (LH2a and LH2b), where LH2b differs from LH2a by incorporating the small exon 13A. LH1 and LH3 hydroxylate lysyl residues in the collagen triple helix, whereas LH2b hydroxylates lysyl residues in the telopeptides of collagen. In addition to its hydroxylation activity, LH3 has glucosylation activity that produces disaccharide (Glc-Gal) attached to collagen hydroxylysines. Collagen lysyl hydroxylation is the first step in collagen pyridinoline cross-linking, that is necessary for the stabilization of collagen.
Sources: en.wikipedia.org
=== Other interactions === SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, NSAIDs, warfarin, or other anticoagulants. Taking citalopram with omeprazole may cause higher blood levels of citalopram. This is a potentially dangerous interaction, so dosage adjustments may be needed or alternatives may be prescribed.
=== Canada === Federally, carisoprodol is a prescription drug. Provincial regulations vary. As of April 2025, no forms of carisoprodol are marketed in Canada, and the drug was removed from the Prescription Drug List and reclassified as a Schedule V Controlled Substance.
=== Overt === In overt primary hypothyroidism, TSH levels are high and T4 levels are low. Overt hypothyroidism may also be diagnosed in those who have a TSH on multiple occasions of greater than 5mIU/L, appropriate symptoms, and only a borderline low T4. It may also be diagnosed in those with a TSH of greater than 10mIU/L.
=== pH and bile tolerance === Testing of L. fermentum against different pH concentration solutions revealed that it has a strong pH tolerance by its ability to grow and survive a few hours after being incubated in a 3-pH level solution. Strains of L. fermentum have also been tested in different bile concentrations and demonstrated to have good bile tolerance when incubated with 3 g L-1 of bile salt. L. fermentum has been found to survive in these conditions further supporting the idea that it can act as a probiotic.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.